Progression-free survival is usually poor (around 8 months) in patients with advanced non-small-cell lung cancer (NSCLC) who have received chemoradiotherapy, and little progress has been made in this field. However, an interim analysis of a phase 3 trial has shown that median progression-free survival significantly lengthened to more than 16 months after treatment with the anti-programmed death ligand-1 antibody durvalumab (compared with less than 6 months with placebo), in patients with stage III disease.

中文翻译：

---

Durvalumab延长了NSCLC患者的生存期

接受放化疗的晚期非小细胞肺癌（NSCLC）患者的无进展生存期通常较差（约8个月），在该领域进展甚微。然而，一项3期临床试验的中期分析显示，在接受抗编程死亡配体1抗体durvalumab治疗后，中位无进展生存期显着延长至16个月以上（与之相比，安慰剂治疗则少于6个月）。 III期疾病患者。